What is the definition, clinical features, diagnostic workup, and management of neonatal onset epilepsy?

Neonatal Onset Epilepsy: Definition, Features, Diagnosis, and Management

Definition

Neonatal seizures are defined as electrographic events with sudden, paroxysmal, and abnormal alteration of brain activity occurring in the first 28 days of life, requiring EEG confirmation for diagnosis. 1 These are divided into:

• Electroclinical seizures: EEG changes with visible clinical manifestations
• Electrographic-only seizures: EEG changes without clinical signs (most common)
• Clinical events without EEG correlation are NOT classified as seizures 2, 1

Most neonatal seizures are acute provoked seizures triggered by brain injury rather than true epilepsy 3. Neonatal-onset epilepsy refers to recurrent unprovoked seizures beginning in the neonatal period, often due to genetic, structural, or metabolic disorders 4.

Clinical Features

Seizure Types (by predominant clinical feature) 1:

Motor seizures:

• Focal clonic: Rhythmic jerking of one limb or body region (only type reliably diagnosed clinically)
• Focal tonic: Sustained posturing of limbs or trunk (only type reliably diagnosed clinically)
• Myoclonic: Brief, shock-like jerks
• Epileptic spasms: Sudden flexion/extension movements
• Automatisms: Oral movements, cycling, swimming motions
• Sequential: Progression through multiple seizure types

Non-motor seizures:

• Autonomic: Apnea, heart rate changes, blood pressure fluctuations
• Behavioral arrest: Sudden cessation of activity with staring

Critical caveat: Only focal clonic and focal tonic seizures can be diagnosed by clinical observation alone—all other types require EEG confirmation 2.

Common Etiologies:

• Hypoxic-ischemic encephalopathy (HIE) - most common
• Stroke (arterial or venous)
• Intracranial hemorrhage
• CNS infections (meningitis, encephalitis)
• Cortical malformations
• Genetic channelopathies (KCNQ2, SCN2A)
• Metabolic disorders (pyridoxine-dependent epilepsy, glucose/electrolyte disturbances)

Diagnosis

EEG monitoring is mandatory for accurate diagnosis—clinical observation alone systematically underestimates seizure burden. 2

Diagnostic Approach:

Immediate EEG monitoring:

• Conventional EEG (gold standard) or amplitude-integrated EEG (aEEG) are both acceptable 2
• Continuous monitoring essential as most seizures are electrographic-only
• Clinical diagnosis without EEG leads to treating non-seizure events and missing true seizures 2

Etiological workup (perform urgently):

• Neuroimaging: MRI brain (preferred) or head ultrasound/CT if MRI unavailable
• Laboratory: Glucose, electrolytes (calcium, magnesium, sodium), blood gas, ammonia, lactate
• Infection screen: Blood culture, lumbar puncture (if not contraindicated)
• Genetic testing: Rapid genomic sequencing, especially if no acute cause identified or family history of seizures 5
• Metabolic screening: Plasma amino acids, urine organic acids if metabolic disorder suspected
• Pyridoxine trial: If refractory to standard treatment or suggestive features present 2

Management

First-Line Treatment

Phenobarbital remains the first-line antiseizure medication (ASM) with the strongest evidence for efficacy (80% seizure control vs 28% for levetiracetam). 2

Dosing:

• Loading dose: 20 mg/kg IV
• May repeat once with additional 20 mg/kg if seizures persist 2

Exception: If family history of channelopathy (KCNQ2/KCNQ3 mutations), use sodium channel blocker (phenytoin or carbamazepine) as first-line instead 2

Critical principle: Use phenobarbital for the shortest duration possible—discontinue before discharge if acute provoked seizures have resolved without evidence of neonatal-onset epilepsy, regardless of MRI or EEG findings 2. This differs from older guidelines and is supported by evidence showing no difference in outcomes at 24 months whether ASMs were continued or discontinued at discharge 2.

Second-Line Treatment

If seizures persist after first-line therapy, use phenytoin or levetiracetam for most etiologies (HIE, stroke, hemorrhage). 2 Midazolam and lidocaine are less favorable alternatives 2.

Etiology-specific considerations:

1. Suspected channelopathy (based on clinical/EEG features): Use sodium channel blocker (phenytoin or carbamazepine) 2

2. Cardiac disorders present: Prefer levetiracetam as second-line 2

3. Refractory seizures without identified etiology OR features suggesting vitamin B6-dependent epilepsy:

   • Trial of pyridoxine (add-on to ASM) 2
   • If unsuccessful, trial pyridoxal-5-phosphate (PLP) 2
   • Do not delay treatment—can start before diagnostic samples collected 2

Treatment Monitoring

• Confirm seizure cessation with EEG/aEEG—clinical assessment alone is inadequate 2
• Assess every 15 minutes after medication administration 2
• Continue monitoring for electrographic-only seizures

Common Pitfalls to Avoid:

1. Relying on clinical observation alone: Misses majority of seizures and treats non-seizure movements 2
2. Continuing ASMs unnecessarily: For acute provoked seizures, discontinue before discharge once controlled 2
3. Delaying phenobarbital: Despite potential adverse effects, it has superior efficacy—use shortest duration necessary 2
4. Missing channelopathies: Ask about family history; these require sodium channel blockers, not phenobarbital 2
5. Not considering pyridoxine-dependent epilepsy: Trial pyridoxine in refractory cases before assuming treatment failure 2

Prognosis

Etiology is the primary determinant of outcome, not seizure burden alone 2. However, reducing seizure burden may improve outcomes based on indirect evidence 2. Long-term neurodevelopmental outcomes vary dramatically based on underlying cause—genetic epilepsies and severe HIE carry worse prognosis than isolated stroke or transient metabolic disturbances.